Sorry, you need to enable JavaScript to visit this website.
Skip to main content
Home

Header Top Menu

  • News & Featured Stories
  • Media
  • Careers
  • Contact Us
  • Our Science

    Sub Menu 1

    • Pfizer in the UK
      • Our History
      • Pharmaceutical Sciences
      • Devices Centre of Excellence
      • Global Regulatory Affairs
      • Material Characterisation Team
      • Anti-Counterfeit Laboratory
    • Our Therapy Areas
      • Anti-Infectives
      • Inflammation and Immunology
      • Internal Medicine
      • Oncology
      • Rare Disease
      • Vaccines

    Sub Menu 2

    • Developing New Medicines
      • Clinical Trials
      • Pipeline
    • Research partnerships
      • ADDoPT
      • Innovative Target Exploration Network (ITEN)
      • INSPIRE Programme
      • Medical Research Council Collaboration
      • The Stratified Medicine Programme
      • Partnership with Regeneron for UK Biobank exome sequencing
    • Breakthroughs that change patients’ lives
    Hot Topic

    Re-shaping Cancer

    Re-shaping cancer
  • Products

    Sub Menu 4

    • Prescription medicines

    Sub Menu 5

    • Safety of Medicines
      • Medicines Regulation
      • Reporting Side Effects
      • Counterfeit Medicines
    Hot Topic

    Vaccines partnerships

    Vaccines partnerships
  • Responsibility

    Sub Menu 7

    • Transparency
      • HCP & HCO Annual Disclosure Reports
      • Healthcare Organisation Grants
      • Research and Development Funding
      • Patient Organisation Funding and Support
    • Codes of Conduct
      • Gender Pay Gap Report
      • Section 172 Statements
      • Pfizer UK Modern Slavery Statement
      • Pfizer UK Tax Strategy

    Sub Menu 8

    • Environmental Sustainability
      • Climate Action
      • Global Actions
      • Our Partnerships & Commitments
      • Sustainable Medicines
      • UK Actions
    • Insurance Details
    • Animal Welfare
    Hot Topic

    Putting Patients First

    Putting Patients First
  • UK Society

    Sub Menu 10

    • Social Investment
      • Volunteering and Fundraising
      • Medicines Donations
    • Raising Public Awareness
      • Change the Course
      • Pfizer Sponsors Science Museum Group's 'Cancer Revolution' Exhibition
      • Pfizer Sponsors the Superhero Series
      • Pfizer sponsors Science Museum exhibition 'Superbugs'
      • Pfizer at the British Science Festival
      • Turning Heads at Westminster

    Sub Menu 11

    • Science Education
      • Developing Science Talent
      • 'Superbugs Join The Fight' School Programme
      • Online Learning
        • Student Education Area
        • Teacher Resources
      • Community Lab
      • Career Talks
      • Lab in a Box
    • Pfizer Worldwide
      • Global Health Fellows
      • Global Aid and Emergency Relief
      • International Trachoma Initiative
    Hot Topic

    'Superbugs' Competition Winners

    Superbugs Winners
  • UK Health System

    Sub Menu 16

    • Working with the NHS and other Healthcare Organisations
      • Collaborative Working
        • Collaborative Working Project between Lloyds Pharmacy and Pfizer Vaccines
        • Joint Working
      • Donations and Grants
        • Independent Medical Grants and Donations
        • Donations of Goods, Services and Benefit in Kind
        • Grants
        • Donations and Grants Enquiry Form
    • Working with Healthcare Professionals
      • FAQs: Working with Healthcare Professionals
      • Pharmacy
      • Healthcare Professionals Congress Sponsorship

    Sub Menu 17

    • Working with Patient Organisations
      • Patient Involvement in Research and Development
      • Our ongoing partnership with the UK Sepsis Trust
      • Partnering with the NIHR and young people on clinical research
    • Pfizer Healthcare Hub
      • Pfizer Healthcare Hub: 2018
      • Pfizer Healthcare Hub: 2017
      • Connect with the Hub
    Hot topic

    Osteoarthritis

    Osteoarthritis
  • News & Featured Stories
  • Media
  • Careers

    Carrers

    • Search Current Vacancies
    • Apprenticeships
      • Apprenticeship Vacancies
    • Undergraduate Placements
      • Undergraduate Vacancies
    • Meet our people
    • UK Top Employer
  • Contact Us
  • Footer links

    Footer mobile menu

    • Footer Menu
    • Footer menu
      • Contact Us
      • Cookie Policy
      • Terms of Use
      • Privacy Policy
      • Sitemap
    • Footer social item
      • Facebook
      • Twitter
      • Instagram
      • YouTube

Vaccines partnerships addressing the diseases of today and tomorrow

Vaccines partnerships addressing the diseases of today and tomorrow
News & Featured Stories/ Vaccines partnerships addressing the diseases of today and tomorrow
23/08/2021

Dr Gillian Ellsbury
Medical director for Vaccines, Pfizer UK & Ireland

Partnerships are how we make scientific breakthroughs and then ensure they translate into medicines and vaccines that reach patients and people in need. No one country or institution has all the answers.

 

Biopharmaceutical companies like Pfizer develop medicines and vaccines and then work with national governments, health authorities and healthcare providers to secure the necessary approvals to distribute them around the world. The response to the COVID-19 pandemic is the perfect illustration of that. That we have come so far and now have multiple vaccines being deployed against this novel virus owes much to that spirit of cooperation and common purpose.

At Pfizer we take our role in this shared endeavour seriously, recognising that we need to work with partners in academia and governments, to achieve results that address some of the world’s greatest health challenges.

That’s why in May we launched the Pfizer Centre of Excellence for Epidemiology of Vaccine-preventable Diseases at the University of Bristol.

Using an initial investment of £4.6 million from Pfizer, the centre will conduct real-world population-based surveillance studies in hospitals and the community to identify and measure the burden of specific infectious diseases affecting adults, including the elderly, as well as children. This data will help us to better understand both the direct and indirect impact that vaccination could have in reducing the consequences of infectious diseases.

Vaccination remains one of the most successful and cost-effective public health interventions – second only to clean water." 

We’ve partnered with the University of Bristol because of its expertise in vaccines research and collaborative links with two NHS Trusts and other health partners. Here at Pfizer, the data gathered through the centre, which is only the second to launch to date and the first outside the US, could also help to inform the design, development and use of next-generation vaccines. 

Vaccination remains one of the most successful and cost-effective public health interventions – second only to clean water.1As well as helping to save lives and improve health, it also has wider economic and social benefits, for example reducing healthcare costs and decreasing lost labour productivity.2 The NHS Long Term Plan has identified respiratory diseases as one of its major priorities over the next 10 years3 and the centre will initially focus on pneumococcal disease – a serious risk in the UK.4 For example, Streptococcus pneumoniae, the bacteria which causes pneumococcal disease,5 is one of the leading causes of community-acquired pneumonia (CAP) in the UK and Europe.6 CAP accounts for approximately 29,000 UK deaths per year and 5–15% of patients hospitalised with the disease will sadly die within 30 days of admission.6

The UK boasts some of the world’s top universities,7 a bold life sciences strategy,8 and Government commitment to increase research funding to £22 billion by 2025,9 making it the perfect place for our second centre of excellence.

Our relationship with the UK’s research base started more than 65 years ago with our site in Sandwich, Kent – one of the world’s first mass production facilities for penicillin.

And running alongside our own medicines development, we collaborate here in the UK with hundreds of researchers and life science partners every year, investing millions of pounds in breakthroughs that change patients’ lives.

 

References

  1. Public Health England. 'Why vaccinate?' (2014) Accessed Nov 2021
  2. Office of Health Economics. 'Realising The Broader Value of Vaccines in the UK: Ready for Prime Time?' (2021) Accessed Nov 2021
  3. NHS Long-Term Plan. 'Better care for major health conditions: Respiratory disease' (2019) Accessed Nov 2021
  4. National Institute for Health and Care Excellence. 'Pneumonia in adults' (2016) Accessed Nov 2021
  5. Centers for Disease Control and Prevention. 'Pneumococcal Disease' Accessed Nov 2021
  6. Chalmers, J., et al. 'Community-acquired pneumonia in the United Kingdom: a call to action'. Pneumonia 2017: 9:15 Accessed Nov 2021
  7. QS Top Universities. The Worlds Top 100 Universities (2021) Accessed Nov 2021
  8. UK Government, 'Bold new life sciences vision sets path for UK to build on pandemic response and deliver life-changing innovations to patients' (2021). Accessed Nov 2021
  9. UK Government. 'The future of UK research: structure and funding' (2020) Accessed Nov 2021

 

PP-VAC-GBR-2002 / November 2021

Related Hot Topics
What is a Variant
What is a Variant?
COVID-19 Vaccine Equity
Working To Reach Everyone, Everywhere
VacciNation report
VacciNation: tackling health inequalities across England
Patients at heart of clinical trials
Why putting patients at the heart of Pfizer UK’s clinical trials continues to…
AMR Explained
Antimicrobial Resistance Explained
Infection Management Coalition Paper
Cross-Industry Coalition Tackling ‘Hidden Pandemic’ of Antibiotic Resistant…
Maternal Immunisation
Protecting Babies from Inside the Womb
Protease Inhibitor
How Does a Protease Inhibitor Work?
Tags
COVID-19
Science / R&D
Vaccines

Footer

  • Contact Us
  • Cookie Policy
  • Terms of Use
  • Privacy Policy
  • Sitemap

Footer aside

  • Footer Aside
    • Facebook
    • Twitter
    • Instagram
    • YouTube

Copyright © 2017-2022 Pfizer Limited. PP-PFE-GBR-4248 / Nov 2021. All rights reserved. Registered in England and Wales No. 526209. Registered office: Ramsgate Road, Sandwich, Kent CT13 9NJ. VAT No. GB201048427